- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03978780
Erector Spinae Block vs. Placebo Block Study
Quality of Recovery Scores Following Erector Spinae Block vs. Sham Block in Ambulatory Breast Cancer Surgery: A Randomised Controlled Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
The ultrasound-guided erector spinae plane (ESP) block has been recently described for the successful management of thoracic neuropathic pain. The erector spinae muscle is formed by the spinalis, longissimus thoracis, and iliocostalis muscles that run vertically in the back. The ESP block is performed by depositing the local anaesthetic in the fascial plane, deep to the erector spinae muscle, at the tip of the transverse process of the vertebra. Indirect access to the paravertebral space is gained providing analgesia without the risk of needle injury to structures in close proximity. Cadaveric studies have shown both ventral and dorsal rami of thoracic spinal nerves are affected when local anaesthetic is injected deep to the erector spinae muscle. The erector spinae muscle extends along the thoracolumbar spine allowing extensive cranio-caudal spread. The ventral ramus (intercostal nerve) is divided into the anterior and lateral branches. Its terminal branches provide the sensory innervation of the entire anterolateral wall. The dorsal ramus is divided into 2 terminal branches and it gives the sensory innervation to the posterior wall. Anterior spread of the local anaesthetic to the paravertebral space through the costotransverse foramina and the intertransverse complex provides both visceral and somatic analgesia.
While recent evidence supports statistically significant reductions in pain and opioid consumption among patients who receive an ESP block compared to systemic analgesia alone, the clinical significance of these differences are questionable the effect of ESP block on the patients' quality of recovery following ambulatory breast cancer surgery remains unclear.
Therefore, our objective is to determine whether or not the addition of an ESP block provides both superior analgesia and quality of recovery in patients undergoing ambulatory breast cancer surgery compared to systemic analgesia alone. We hypothesis that patients who received a preoperative ESP block will afford superior postoperative analgesia and improve the quality of recovery over the first 24 hours following surgery compared to those who receive a sham block for their ambulatory breast cancer surgery.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Didem Bozak
- Phone Number: 416-323-6008
- Email: didem.bozak@wchospital.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5S 1B2
- Women's College Hospital
-
Contact:
- Richard Brull, MD
- Phone Number: 4239 416-323-6400
- Email: richard.brull@wchospital.ca
-
Contact:
- Didem Bozak
- Phone Number: 6008 416-323-6400
- Email: didem.bozak@wchospital.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ASA classification: I-III
- BMI < 35 kg/m2
- Day surgery procedure
Exclusion Criteria:
- Prior ipsilateral breast surgery, excluding lumpectomy
- Pre-existing neurological deficit or peripheral neuropathy involving the ipsilateral chest
- Severe, poorly controlled cardiac conditions, significant arrhythmias, severe valvular heart diseases
- Severe, poorly controlled respiratory conditions (severe COPD, severe interstitial lung disease, severe / poorly controlled asthma)
- Contraindication to regional anaesthesia (e.g. bleeding diathesis, coagulopathy, sepsis, infection at the site of potential needle puncture on the posterior chest)
- Patient refusal
- Chronic pain disorder
- Chronic opioid use (≥30 mg oxycodone / day)
- Contraindication (or allergy) to a component of multi-modal analgesia protocol
- Allergy to amide local anaesthetics used in nerve blocks
- Contraindications to any of the components of the standardized general anaesthesia
- Significant psychiatric disorder that would preclude objective study assessment
- Pregnancy/ women with nursing infants
- Unable to provide informed consent
- Unable to speak and read English
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Control Group
Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block (see above) under ultrasound guidance to stimulate a real block procedure.
|
Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block under ultrasound guidance to stimulate a real block procedure.
|
|
Experimental: Erector spinae plane (ESP) block group
Local anaesthetic infiltration utilising 1% lidocaine will occur, and an 80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process.
Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed.
|
80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process.
Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acute postoperative pain at rest
Time Frame: 24 hours postoperatively
|
Following breast surgery, measured as an area under the curve (AUC) of rest pain scores VAS scale where 0 corresponds to no pain, and 10 corresponds to worst pain imaginable
|
24 hours postoperatively
|
|
Quality of postoperative recovery (QoR 15)
Time Frame: 24 hours post-surgery
|
Quality of recovery at 24 hours: questionnaire (0-10, where 0 = none of the time [poor] and 10 = all of the time [excellent])
|
24 hours post-surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative pain scores
Time Frame: 0, 6, 12, 18, 24 and 48 hours post-operatively
|
VAS scale where 0 corresponds to no pain, and 10 corresponds to worst pain imaginable
|
0, 6, 12, 18, 24 and 48 hours post-operatively
|
|
Intraoperative opioid consumption
Time Frame: During the procedure
|
Cumulative oral morphine equivalent after surgery
|
During the procedure
|
|
Postoperative opioid consumption
Time Frame: 12,24,48 hours, 7 days postoperative
|
Cumulative oral morphine equivalent after surgery
|
12,24,48 hours, 7 days postoperative
|
|
Duration of phase I (PACU) and phase II (surgical day care, SDC) stay
Time Frame: From end of surgical procedure to 24 hours after surgery
|
How fast is the recovery is-expressed in minutes
|
From end of surgical procedure to 24 hours after surgery
|
|
Opioid-related side effects
Time Frame: End of surgical procedure to 48 hours after surgery
|
Risk of opioid-related side effects(nausea, vomiting, pruritis)
|
End of surgical procedure to 48 hours after surgery
|
|
Persistent post surgical pain DN4 screening tool
Time Frame: 3 months post operatively
|
Satisfaction with pain management.
Is prescribed pain medication enough?
|
3 months post operatively
|
|
Block-related complications
Time Frame: End of surgical procedure to 48 hours after surgery
|
bruising at injection site, numbness over lateral chest, weakness of shoulder or arm, pain/swelling at injection site
|
End of surgical procedure to 48 hours after surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Richard Brull, MD,FRCPC, Women's College Hospital
Publications and helpful links
General Publications
- Forero M, Adhikary SD, Lopez H, Tsui C, Chin KJ. The Erector Spinae Plane Block: A Novel Analgesic Technique in Thoracic Neuropathic Pain. Reg Anesth Pain Med. 2016 Sep-Oct;41(5):621-7. doi: 10.1097/AAP.0000000000000451.
- Blanco R, Parras T, McDonnell JG, Prats-Galino A. Serratus plane block: a novel ultrasound-guided thoracic wall nerve block. Anaesthesia. 2013 Nov;68(11):1107-13. doi: 10.1111/anae.12344. Epub 2013 Aug 7.
- Gurkan Y, Aksu C, Kus A, Yorukoglu UH, Kilic CT. Ultrasound guided erector spinae plane block reduces postoperative opioid consumption following breast surgery: A randomized controlled study. J Clin Anesth. 2018 Nov;50:65-68. doi: 10.1016/j.jclinane.2018.06.033. Epub 2018 Jul 2.
- Mazzinari G, Rovira L, Casasempere A, Ortega J, Cort L, Esparza-Minana JM, Belaouchi M. Interfascial block at the serratus muscle plane versus conventional analgesia in breast surgery: a randomized controlled trial. Reg Anesth Pain Med. 2019 Jan;44(1):52-58. doi: 10.1136/rapm-2018-000004.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-0048-B
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Placebo Block
-
Helse Møre og Romsdal HFOslo University Hospital; St. Olavs Hospital; The Nordmøre and Romsdal Hospital...Not yet recruitingTotal Knee Arthroplasty | Osteoarthritis (OA) of the Knee | Genicular Nerve BlockNorway
-
Glostrup University Hospital, CopenhagenCompletedLaparoscopic CholecystectomyDenmark
-
NYU Langone HealthCompleted
-
Konya City HospitalRecruitingAcute Postoperative Pain | Thoracotomy Surgery | Intertransverse Process BlockTurkey (Türkiye)
-
Second Affiliated Hospital, School of Medicine,...RecruitingAnkle Ligament Injury,Chronic Ankle Instability,Ankle ArthroscopyChina
-
Pontificia Universidad Catolica de ChileCompletedKnee Osteoarthritis | Total Knee Arthroplasty | Nerve BlockChile
-
Taipei Medical University HospitalRecruitingPostoperative Pain | HemorrhoidsTaiwan
-
Cairo UniversityRecruitingAdenotonsillectomy | RegionalEgypt
-
Liverpool University Hospitals NHS Foundation TrustCompletedPain | Disorder Related to Renal TransplantationUnited Kingdom
-
London Health Sciences Centre Research Institute...Not yet recruiting